Anna Lusakowska1, Maria Jedrzejowska2, Anna Kaminska1, Katarzyna Janiszewska1, Przemysław Grochowski3, Janusz Zimowski4, Janusz Sierdzinski5, Anna Kostera-Pruszczyk6. 1. Department of Neurology, European Reference Network EURO-NMD, Medical University of Warsaw, Warsaw, Poland. 2. Rare Diseases Research Platform, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland. 3. Student Research Group of Department of Neurology, Medical University of Warsaw, Warsaw, Poland. 4. Department of Genetics, Institute of Psychiatry and Neurology, Warsaw, Poland. 5. Department of Medical Informatics and Telemedicine, Medical University of Warsaw, Warsaw, Poland. 6. Department of Neurology, European Reference Network EURO-NMD, Medical University of Warsaw, Warsaw, Poland. anna.kostera-pruszczyk@wum.edu.pl.
Abstract
BACKGROUND: Spinal muscular atrophy (SMA) is one of the most frequent and severe genetic diseases leading to premature death or severe motor disability. New therapies have been developed in recent years that change the natural history of the disease. The aim of this study is to describe patients included in the Polish Registry of SMA, with a focus on the course of type 3 SMA (SMA3) before the availability of disease-modifying treatments. RESULTS: 790 patients with SMA were included in the registry (173 with type 1 [SMA1], 218 with type 2 [SMA2], 393 with SMA3, and six with type 4 SMA [SMA4]), most (52%) of whom were adults. Data on SMN2 gene copy number were available for 672 (85%) patients. The mean age of onset was 5 months for SMA1, 11.5 months for SMA2, and 4.5 years for SMA3. In patients with SMA3, the first symptoms occurred earlier in those with three copies of SMN2 than in those with four copies of SMN2 (3.2 years vs. 6.7 years). The age of onset of SMA3 was younger in girls than in boys (3.1 years vs. 5.7 years), with no new cases observed in women older than 16 years. Male patients outnumbered female patients, especially among patients with SMA3b (49 female vs. 85 male patients) and among patients with SMA3 with four copies of SMN2 (30 female vs. 69 male patients). 44% of patients with SMA3 were still able to walk; in those who were not still able to walk, the mean age of immobilization was 14.0 years. Patients with SMA3a (age of onset < 3 years) and three copies of SMN2 had significantly worse prognosis for remaining ambulant than patients with SMA3b (age of onset ≥ 3 years) and four copies of SMN2. CONCLUSIONS: The Registry of SMA is an effective tool for assessing the disease course in the real world setting. SMN2 copy number is an important prognostic factor for the age of onset and ambulation in SMA3. Sex and age of disease onset also strongly affect the course of SMA. Data supplied by this study can aid treatment decisions.
BACKGROUND:Spinal muscular atrophy (SMA) is one of the most frequent and severe genetic diseases leading to premature death or severe motor disability. New therapies have been developed in recent years that change the natural history of the disease. The aim of this study is to describe patients included in the Polish Registry of SMA, with a focus on the course of type 3 SMA (SMA3) before the availability of disease-modifying treatments. RESULTS: 790 patients with SMA were included in the registry (173 with type 1 [SMA1], 218 with type 2 [SMA2], 393 with SMA3, and six with type 4 SMA [SMA4]), most (52%) of whom were adults. Data on SMN2 gene copy number were available for 672 (85%) patients. The mean age of onset was 5 months for SMA1, 11.5 months for SMA2, and 4.5 years for SMA3. In patients with SMA3, the first symptoms occurred earlier in those with three copies of SMN2 than in those with four copies of SMN2 (3.2 years vs. 6.7 years). The age of onset of SMA3 was younger in girls than in boys (3.1 years vs. 5.7 years), with no new cases observed in women older than 16 years. Male patients outnumbered female patients, especially among patients with SMA3b (49 female vs. 85 male patients) and among patients with SMA3 with four copies of SMN2 (30 female vs. 69 male patients). 44% of patients with SMA3 were still able to walk; in those who were not still able to walk, the mean age of immobilization was 14.0 years. Patients with SMA3a (age of onset < 3 years) and three copies of SMN2 had significantly worse prognosis for remaining ambulant than patients with SMA3b (age of onset ≥ 3 years) and four copies of SMN2. CONCLUSIONS: The Registry of SMA is an effective tool for assessing the disease course in the real world setting. SMN2 copy number is an important prognostic factor for the age of onset and ambulation in SMA3. Sex and age of disease onset also strongly affect the course of SMA. Data supplied by this study can aid treatment decisions.
Entities:
Keywords:
Neuromuscular disease; Registry; SMN2 copy number; Spinal muscular atrophy (SMA); TREAT-NMD; Type 3 SMA
Authors: Renske I Wadman; Marloes Stam; Marleen Gijzen; Henny H Lemmink; Irina N Snoeck; Camiel A Wijngaarde; Kees P J Braun; Marja A G C Schoenmakers; Leonard H van den Berg; Dennis Dooijes; W-Ludo van der Pol Journal: J Neurol Neurosurg Psychiatry Date: 2017-01-20 Impact factor: 10.154
Authors: Laura Alías; Sara Bernal; Pablo Fuentes-Prior; María Jesus Barceló; Eva Also; Rebeca Martínez-Hernández; Francisco J Rodríguez-Alvarez; Yolanda Martín; Elena Aller; Elena Grau; Ana Peciña; Guillermo Antiñolo; Enrique Galán; Alberto L Rosa; Miguel Fernández-Burriel; Salud Borrego; José M Millán; Concepción Hernández-Chico; Montserrat Baiget; Eduardo F Tizzano Journal: Hum Genet Date: 2008-12-03 Impact factor: 4.132
Authors: Maria Jedrzejowska; Michał Milewski; Janusz Zimowski; Janina Borkowska; Anna Kostera-Pruszczyk; Danuta Sielska; Marta Jurek; Irena Hausmanowa-Petrusewicz Journal: Acta Biochim Pol Date: 2009-03-14 Impact factor: 2.149
Authors: Maria Jedrzejowska; Michal Milewski; Janusz Zimowski; Pawel Zagozdzon; Anna Kostera-Pruszczyk; Janina Borkowska; Danuta Sielska; Marta Jurek; Irena Hausmanowa-Petrusewicz Journal: Neuroepidemiology Date: 2010-01-15 Impact factor: 3.282
Authors: S Lefebvre; L Bürglen; S Reboullet; O Clermont; P Burlet; L Viollet; B Benichou; C Cruaud; P Millasseau; M Zeviani Journal: Cell Date: 1995-01-13 Impact factor: 41.582
Authors: Michelle A Farrar; Susanna B Park; Steve Vucic; Kate A Carey; Bradley J Turner; Thomas H Gillingwater; Kathryn J Swoboda; Matthew C Kiernan Journal: Ann Neurol Date: 2017-02-17 Impact factor: 10.422
Authors: Lisa Belter; Suzanne F Cook; Thomas O Crawford; Jill Jarecki; Cynthia C Jones; John T Kissel; Mary Schroth; Kenneth Hobby Journal: J Neuromuscul Dis Date: 2018